Brazilian Group of Gastrointestinal Tumors, Brazil
Posters & Accepted Abstracts: J Cancer Sci Ther
A substantial number of observational and interventional studies support the role of aspirin as preventive agent in many types of cancer, especially in colorectal cancer (CRC). Both the inhibition of COX-1 and COX-2 are implicated in the mechanism of action of aspirin and are important in the role of chemoprevention in CRC. However, in the neoplastic transformation, COX-2 positive, wild type BRAF and PIK3CA-mutated tumors appear to be more sensitive to this agent. Low dose aspirin (75-325 mg), used for at least 5 years, appear to reduce the incidence of adenomas, gastrointestinal tumors and CRC mortality. Those benefits apply not only for the general population but also for people with pre-existing adenomas and CRC history.
Cancer Science & Therapy received 3644 citations as per Google Scholar report